{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:23:20Z","timestamp":1789190600620,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.lungcan.2025.108452","type":"journal-article","created":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T18:11:34Z","timestamp":1739729494000},"page":"108452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3017-1567","authenticated-orcid":false,"given":"Jamie","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Hueniken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen Jason","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna Jia","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Faour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Corke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Alghabban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-4602","authenticated-orcid":false,"given":"Natasha B.","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2603-7296","authenticated-orcid":false,"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope A.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawson","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4476-9722","authenticated-orcid":false,"given":"Tracy L.","family":"Stockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Sound","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3610-3533","authenticated-orcid":false,"given":"Frances A.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108452_b0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0010","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.3390\/curroncol29070396","article-title":"Consensus recommendations to optimize testing for new targetable alterations in non-small cell lung cancer","volume":"29","author":"Ionescu","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0015","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1200\/JCO.22.00824","article-title":"Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO living guideline","volume":"40","author":"Singh","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0020","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.3390\/curroncol29070352","article-title":"Upfront next generation sequencing in non-small cell lung cancer","volume":"29","author":"Kuang","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0025","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Collisson","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2025.108452_b0030","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1126\/science.2554494","article-title":"p53: a frequent target for genetic abnormalities in lung cancer","volume":"246","author":"Takahashi","year":"1989","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.lungcan.2025.108452_b0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2017.06.014","article-title":"Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)","volume":"111","author":"Labbe","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108452_b0040","doi-asserted-by":"crossref","unstructured":"C. Aggarwal et al. Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non\u2013Small-Cell Lung Cancer. https:\/\/doi.org\/10.1200\/PO.18.00107 1\u201329 (2018) doi:10.1200\/PO.18.00107.","DOI":"10.1200\/PO.18.00107"},{"key":"10.1016\/j.lungcan.2025.108452_b0045","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-16-0966","article-title":"Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors","volume":"23","author":"Canale","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108452_b0050","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","article-title":"Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance","volume":"24","author":"Yu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108452_b0055","article-title":"Harnessing clinical sequencing data for survival stratification of patients with metastatic lung adenocarcinomas","volume":"1\u20139","author":"Shen","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103929","article-title":"Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors","volume":"184","author":"Ferrara","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.lungcan.2025.108452_b0065","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jtho.2022.02.011","article-title":"Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma","volume":"17","author":"Vokes","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0070","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1038\/s41467-024-47606-9","article-title":"Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling","volume":"15","author":"Hobor","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.lungcan.2025.108452_b0075","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1535-7163.MCT-19-0105","article-title":"Analysis of the genomic landscape in ALK+ NSCLC patients identifies novel aberrations associated with clinical outcomes","volume":"18","author":"du Tertre","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2025.108452_b0080","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/annonc\/mdy333","article-title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","volume":"29","author":"Kron","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0085","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2022.04.020","article-title":"The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions","volume":"170","author":"Christopoulos","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2025.108452_b0090","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/1078-0432.CCR-17-2289","article-title":"The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations-the lung cancer mutation consortium (LCMC2)","volume":"24","author":"Aisner","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108452_b0095","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/j.cllc.2018.10.003","article-title":"Natural disease history, outcomes, and co-mutations in a series of patients with BRAF-mutated non-small-cell lung cancer","volume":"20","author":"Myall","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108452_b0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-020-00866-6","article-title":"Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study","volume":"13","author":"Lu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0105","article-title":"Prognosis and concurrent genomic alterations in patients with advanced NSCLC harboring MET amplification or MET Exon 14 skipping mutation treated with MET inhibitor: a retrospective study","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0110","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(Ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0115","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1002\/cncr.32422","article-title":"Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: a Canadian reference testing center\u2019s results in population\u2010based reflex testing","volume":"125","author":"Fiset","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2025.108452_b0120","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1200\/JCO.2016.71.2893","article-title":"Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy","volume":"35","author":"Shepherd","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0125","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1056\/NEJMoa073770","article-title":"TP53 mutations and survival in squamous-cell carcinoma of the head and neck","volume":"357","author":"Poeta","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2025.108452_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020429","article-title":"Drugs targeting p53 mutations with FDA approval and in clinical trials","volume":"15","author":"Nishikawa","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2025.108452_b0135","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2021.06.012","article-title":"Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC","volume":"158","author":"Zhang","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108452_b0140","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12885-020-06805-5","article-title":"Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis","volume":"20","author":"Qin","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2025.108452_b0145","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jtho.2023.07.023","article-title":"Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced NSCLC in relation to EML4::ALK variant type and ALK with or without TP53 mutations","volume":"18","author":"Bearz","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0150","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.lungcan.2025.108452_b0155","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0160","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR -mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2025.108452_b0165","doi-asserted-by":"crossref","first-page":"S1306","DOI":"10.1016\/j.annonc.2023.10.062","article-title":"LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial","volume":"34","author":"Cho","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0170","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jtho.2023.12.007","article-title":"Chemotherapy and osimertinib combination should not be the first-line treatment for all advanced EGFR+ NSCLC","volume":"19","author":"Lim","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.05.541","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","author":"Felip","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0180","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jtho.2021.05.006","article-title":"Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE study (CTONG1706)","volume":"16","author":"Zhao","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0185","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cllc.2023.02.010","article-title":"RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+ NSCLC): association between TP53 status and clinical outcome","volume":"24","author":"Nishio","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108452_b0190","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.24.00533","article-title":"A multicenter open-label randomized phase II study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor\u2013na\u00efve EGFR -mutant metastatic non\u2013small cell lung cancer (RAMOSE trial)","volume":"43","author":"Le","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.lungcan.2025.108452_b0195","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","article-title":"Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC Harboring EGFR mutations: WJOG9717L study","volume":"17","author":"Kenmotsu","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0200","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12890-023-02472-x","article-title":"Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis","volume":"23","author":"Hu","year":"2023","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.lungcan.2025.108452_b0205","doi-asserted-by":"crossref","first-page":"615","DOI":"10.21037\/tlcr-22-708","article-title":"Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review","volume":"12","author":"Desai","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108452_b0210","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9144","volume":"40","author":"Duruisseaux","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.lungcan.2025.108452_b0215","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1038\/s41467-023-40793-x","article-title":"Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis","volume":"14","author":"Skakodub","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2025.108452_b0220","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JOP.19.00722","article-title":"Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline summary","volume":"16","author":"Schneider","year":"2020","journal-title":"JCO Oncol. Practice"},{"key":"10.1016\/j.lungcan.2025.108452_b0225","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR -mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108452_b0230","doi-asserted-by":"crossref","first-page":"S1295","DOI":"10.1016\/j.annonc.2023.10.051","article-title":"LBA2 ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0235","doi-asserted-by":"crossref","first-page":"250","DOI":"10.18632\/oncotarget.27430","article-title":"TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC","volume":"11","author":"Roeper","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2025.108452_b0240","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","article-title":"p53 signaling in cancer progression and therapy","volume":"21","author":"Marei","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.lungcan.2025.108452_b0245","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3390\/cancers14051143","article-title":"The role of TP53 mutations in EGFR-mutated non-small-cell lung cancer: clinical significance and implications for therapy","volume":"14","author":"Canale","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2025.108452_b0250","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1097\/JTO.0000000000000584","article-title":"Inhibiting MDM2-p53 interaction suppresses tumor growth in patient-derived non\u2013small cell lung cancer xenograft models","volume":"10","author":"Hai","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108452_b0255","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3390\/curroncol30020143","article-title":"Harnessing real-world evidence to advance cancer research","volume":"30","author":"Tang","year":"2023","journal-title":"Curr. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022500073X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022500073X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T20:22:20Z","timestamp":1753993340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022500073X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":51,"alternative-id":["S016950022500073X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108452","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108452"}}